Reuters reported the MHRA authorization on August 10, 2026. Foundayo was approved for weight management and type 2 diabetes. Britain became the first European country to authorize Foundayo for both conditions. It is the second oral GLP-1 pill cleared in the UK after oral Wegovy. Lilly said the product would launch later in August through private prescription.
MHRA Makes Britain Foundayo’s First European Market
The MHRA authorized Lilly’s Foundayo for weight management and type 2 diabetes, making the UK the first European country to approve the tablet for both conditions. Readers should treat this development as evidence, not a guaranteed forecast for future hiring.
Foundayo became the second oral GLP-1 medicine cleared in Britain after Novo Nordisk’s Wegovy pill received its UK authorization in June 2026. This context helps readers make more focused career decisions today. This evidence supports focused pharmaceutical career decisions today.
Private Launch Is Planned for August
Lilly told Reuters that Foundayo would launch later in August through private prescription and would have a lower private UK list price than Mounjaro. This evidence supports focused pharmaceutical career decisions today. This evidence supports focused pharmaceutical career decisions today.
EU Review Continues Beyond the UK Decision
Foundayo remains under review in the European Union, while oral Wegovy has received a positive EMA recommendation and awaits a European Commission decision. That context helps readers make more focused career decisions. This evidence supports focused pharmaceutical career decisions today.
Oral Competition Expands a Mostly Injectable Market
The competitive context extends beyond approval because oral products are entering a market still led by injectable GLP-1 therapies with established efficacy and weekly. This evidence supports focused pharmaceutical career decisions today. This evidence supports focused pharmaceutical career decisions today.
Labeling teams must ensure approved indications, dosing, administration, warnings, and product information are reflected accurately in controlled materials used for the UK market. That context helps readers make more focused career decisions. This evidence supports focused pharmaceutical career decisions today.
Pharmacovigilance Continues After Approval
Pharmacovigilance continues after authorization through adverse-event collection, signal evaluation, reporting, risk management, and ongoing benefit-risk assessment as patient exposure expands in routine use. That context helps readers make more focused career decisions. This evidence supports focused pharmaceutical career decisions today.
Medical Affairs Supports Scientific Communication
Medical affairs supports scientific communication about the approved medicine, helping respond to healthcare-professional questions and communicate evidence within the boundaries of the authorized product. This evidence supports focused pharmaceutical career decisions today. This evidence supports focused pharmaceutical career decisions today.
To connect the MHRA’s Foundayo approval with the people who manage approvals and post-approval obligations, read Pharmuni’s Regulatory Affairs Pharma Jobs in 2026: Roles & Salary Guide. It explains regulatory affairs roles, FDA/EMA requirements, submission planning, labeling changes, lifecycle commitments, and the skills professionals use across regulated product pathways.